



I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 29th day of January 2004.

By _____

(Signature of person mailing)

Heather Randhahn

(Typed or printed name of person)

Patent Application
Docket No. PC11861A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
LOMBARDO, FRANCO, ET AL.
Serial No.: 10/081,784
Filed: February 21, 2002
For: TOOL FOR LIOPHILICITY
DETERMINATION IN DRUG
DISCOVERY BASIC AND
NEUTRAL COMPOUNDS

Group Art Unit: 1743

Examiner: LUDLOW, JAN M.

TERMINAL DISCLAIMER UNDER
37 C.F.R. §1.321(c)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir;

Pfizer Inc., the owner of 100 percent interest in the instant U.S. patent application, hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§154 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,548,307 B2. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors, or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§154 and 173 of the prior patent, as

presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

The undersigned is an attorney of record in the instant application.

Please charge the \$110.00 fee due under 37 C.F.R. §1.20(d) to Deposit Account No.16-1445. The Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment, to Deposit Account No. 16-1445. Two (2) copies of this sheet are enclosed herewith.

Respectfully submitted,

Date: January 29, 2004



Nicholas I. Slepchuk, Jr.
Attorney for Applicants
Registration No. 32,174

Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(617) 551-3223